Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range of 27.2 million to 39.3 million yuan, representing a year-on-year decrease of 35% to 55% due to increased expenses in various areas [1] Financial Performance - The anticipated decline in net profit is attributed to increased sales expenses from intensified efforts in the formulation market [1] - Management expenses have risen due to payments related to restructuring and intermediary fees [1] - Research and development expenses have increased as the company continues to invest in new product development and improve its R&D management system [1] - Other income has decreased due to a reduction in government subsidies related to daily operations [1] - The company has conducted a comprehensive review of its receivables and other assets, leading to an increase in asset impairment losses as it prepares for potential write-downs [1]
科源制药：预计2025年度净利润为2720.19万元~3929.16万元，同比下降35%~55%